Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $2.1 billion.

  • Avidity Biosciences' Liabilities and Shareholders Equity rose 30.07% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 42.86%. This contributed to the annual value of $1.6 billion for FY2024, which is 148.81% up from last year.
  • Latest data reveals that Avidity Biosciences reported Liabilities and Shareholders Equity of $2.1 billion as of Q3 2025, which was up 55.90% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Liabilities and Shareholders Equity peaked at $2.1 billion during Q3 2025, and registered a low of $290.5 million during Q2 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.3 billion (2024), whereas its average is $1.2 billion.
  • As far as peak fluctuations go, Avidity Biosciences' Liabilities and Shareholders Equity dropped by 18.24% in 2021, and later soared by 186.27% in 2024.
  • Over the past 5 years, Avidity Biosciences' Liabilities and Shareholders Equity (Quarterly) stood at $427.6 million in 2021, then skyrocketed by 49.40% to $638.8 million in 2022, then decreased by 1.60% to $628.6 million in 2023, then soared by 148.81% to $1.6 billion in 2024, then surged by 30.07% to $2.1 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.1 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.